insights_auto
Mengapa ADAPY turun 25,40%?
Pelajari Lebih Lanjutchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$0,024
arrow_downward
-25,40%(-0,0080) 1 HR
18 Nov, 16.00.00 GMT-5 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk ADAPY...
Pembukaan
US$0,02
Tinggi
US$0,04
Rendah
US$0,02
Kapitalisasi pasar
6,54 jt
Volume rata-rata
328,69 rb
Volume
433,33 rb
Harga tinggi dalam 52 minggu terakhir
US$0,07
Harga rendah dalam 52 minggu terakhir
US$0,00
Beta
0,87
Saham beredar
265,05 jt
Jumlah karyawan
272
Pembukaan
US$0,02
Tinggi
US$0,04
Rendah
US$0,02
Kapitalisasi pasar
6,54 jt
Volume rata-rata
328,69 rb
Volume
433,33 rb
Harga tinggi dalam 52 minggu terakhir
US$0,07
Harga rendah dalam 52 minggu terakhir
US$0,00
Beta
0,87
Saham beredar
265,05 jt
Jumlah karyawan
272
Artikel berita
Dari sumber web dan partner berita
The Business Journal
·
10 jam yang lalu
S&P 500 losing streak hits five days
Benzinga
·
3 jam yang lalu
Stock Market: Will S&P 500 Open Up or Down Today? - State Street SPDR S&P 500 ETF Trust (ARCA:SPY)
Hedgeye
·
19 jam yang lalu
Why Negative Gamma Has Taken the Brakes Off the S&P 500
The Motley Fool
·
12 jam yang lalu
ExxonMobil (XOM) Just Achieved Something 95% of S&P 500 (GSPC) Members Haven't Done
Profil
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Tentang Adaptimmune Therapeutics PLC - ADR
CEOAdrian Rawcliffe
Karyawan272
Didirikan2008
Kantor Pusat-
SektorHealth Care
Industri-
Situsadaptimmune.com